[1000units]

This is a very odd characterization! Looking at Turing's 2014 10-K, I see this as a listed strategy:

Focus on developing products to treat rare diseases characterized by severe unmet medical needs.

I also see several preclinical programs and product candidates. You must have missed those. Odd case, very strange.